Edition:
United Kingdom

Lupin Ltd (LUPN.NS)

LUPN.NS on National Stock Exchange of India

807.50INR
23 Feb 2018
Change (% chg)

Rs7.45 (+0.93%)
Prev Close
Rs800.05
Open
Rs803.10
Day's High
Rs814.80
Day's Low
Rs803.10
Volume
1,754,473
Avg. Vol
2,145,065
52-wk High
Rs1,498.00
52-wk Low
Rs781.80

Select another date:

Wed, Feb 21 2018

BRIEF-Lupin Launches Generic Namenda Xr Capsules In U.S.‍​

* SAYS DRUG IS INDICATED FOR TREATMENT OF MODERATE TO SEVERE DEMENTIA OF ALZHEIMER'S TYPE‍​ Source text: http://bit.ly/2oh09C4 Further company coverage:

BRIEF-India's Lupin Gets U.S. ‍FDA Nod For Generic Tamiflu

* GETS U.S. ‍FDA APPROVAL FOR GENERIC TAMIFLU FOR ORAL SUSPENSION​ Source text - http://bit.ly/2sPD9z5 Further company coverage:

BRIEF-Lupin Gets Tentative FDA Approval For Generic Locoid Lotion

* GETS TENTATIVE FDA APPROVAL FOR GENERIC LOCOID LOTION Source text: [Lupin Limited has informed the Exchange regarding a press release dated February 12, 2018, titled "Lupin receives tentative FDA approval for generic Locoid® Lotion.".] Further company coverage:

BRIEF-Lupin Launches Generic Tamiflu In U.S. ‍​

* LAUNCHES GENERIC TAMIFLU® IN THE U.S. ‍​ Source text: http://bit.ly/2o0TlHP Further company coverage:

BRIEF-Lupin Launches Generic Kapvay Tablets In The U.S.

* SAYS CO LAUNCHES GENERIC KAPVAY TABLETS IN THE U.S. Source text - http://bit.ly/2GYrhxJ Further company coverage:

BRIEF-Lupin's JV YL Biologics Says Phase III Clinical Trial Of YLB113 Met With Successful Outcome

* JV YL BIOLOGICS SAYS PHASE III CLINICAL TRIAL OF INVESTIGATIONAL ETANERCEPT BIOSIMILAR (YLB113) HAS MET WITH SUCCESSFUL OUTCOME Source text: http://bit.ly/2GUNAnF Further company coverage:

UPDATE 1-India's Lupin Q3 profit misses estimates on lower sales in North America, forex losses

* Forex loss of 821 mln rupees (Adds details, comment from managing director)

BRIEF-India's Lupin Dec Qtr Consol Profit Falls 65 Pct

* DEC QUARTER CONSOL NET PROFIT AFTER TAX 2.22 BILLION RUPEES VERSUS PROFIT OF 6.33 BILLION RUPEES LAST YEAR

BRIEF-Lupin Ltd Qtrly Performance Muted On Back Of Business Mix, Forex Losses

* SAYS QTRLY PERFORMANCE WAS MUTED ON BACK OF BUSINESS MIX AS WELL AS FOREX LOSSES

India's Lupin Q3 profit down 65 pct, misses estimates

Feb 6 Lupin Ltd, India's second-largest drugmaker by revenue, on Tuesday posted a 65 percent fall in third-quarter net profit, well below analysts' estimates.

Select another date: